Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S ADR
(NY:
NVO
)
120.78
-3.52 (-2.83%)
Streaming Delayed Price
Updated: 10:10 AM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novo Nordisk A/S ADR
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
61
62
Next >
Why Novo Nordisk Stock Is Slipping Today
July 02, 2024
President Biden and Sen. Bernie Sanders warned the drugmaker against "ripping off the American people."
Via
The Motley Fool
Joe Biden Suggests Novo Nordisk, Eli Lilly To Lower Prices For Its Popular Obesity Drugs
July 02, 2024
American leaders push for lower drug prices, highlighting recent legislation and widespread support for affordable medications. The Inflation Reduction Act caps insulin costs and Medicare now...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Novo, Lilly Dive After Biden Slams Duo For 'Unconscionably High' Drug Prices
July 02, 2024
The duo make weight-loss and diabetes drugs that sell for more than $1,000 a month before insurance kicks in.
Via
Investor's Business Daily
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
July 02, 2024
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy
Via
MarketBeat
3 Under-the-Radar Biotech Stocks With Blockbuster Potential
July 02, 2024
Are you looking to boost your portfolio with the best under-the-radar biotech stocks? Here are the top three.
Via
InvestorPlace
Beyond The Numbers: 8 Analysts Discuss Novo Nordisk Stock
July 01, 2024
Via
Benzinga
Novo Nordisk Options Trading: A Deep Dive into Market Sentiment
June 28, 2024
Via
Benzinga
Should you consider NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) for quality investing?
June 28, 2024
Why NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) qualifies as a quality stock.
Via
Chartmill
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
July 01, 2024
Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound.
Via
MarketBeat
Exposures
Product Safety
3 Breakout Biotech Stocks on Track to Double by 2032
July 01, 2024
The tech sector has been at the forefront of the market rally in 2024. Consider these breakout biotech stocks as a great way to diversify.
Via
InvestorPlace
Week In Review: Fosun Pharma Plans $690 Million Deal To Privatize Henlius, Its Biologics Subsidiary
June 30, 2024
Shanghai Henlius Biotech agreed to be a wholly owned subsidiary of Fosun in a $690 million deal that values the company at $1.7 billion. Meanwhile, Suzhou Ascentage Pharma filed to list in the US to...
Via
Talk Markets
Surprise! Novo Nordisk's Wegovy Just Achieved Another Milestone. Here's What You Need to Know.
June 30, 2024
Wegovy was just approved in China.
Via
The Motley Fool
If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy
June 29, 2024
The market for weight loss medicines keeps getting hotter and hotter.
Via
The Motley Fool
This Is Massive News for Eli Lilly Investors
June 29, 2024
A panel of advisors to the Food and Drug Administration (FDA) recently recommended Eli Lilly's Alzheimer's candidate.
Via
The Motley Fool
Eli Lilly Is Teaming Up With OpenAI. Here Are 3 Things Smart Investors Should Know.
June 29, 2024
Eli Lilly is the latest major pharmaceutical company to bring artificial intelligence (AI) to the healthcare sector.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Stock Market Rally Powers To Fresh Highs; Carnival, Micron, Nike In Focus: Weekly Review
June 28, 2024
Software, small caps and megacaps were standouts.
Via
Investor's Business Daily
The Top 3 Weight Loss Drug Stocks to Buy for Huge Gains
June 28, 2024
Consider buying shares in these pharma companies, each of which is a leader in the weight loss drug sector.
Via
InvestorPlace
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
June 28, 2024
These healthcare stocks have clear paths to growth over the next few years.
Via
The Motley Fool
Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
June 27, 2024
2seventy Bio finalized an asset purchase agreement with Novo Nordisk involving the Hemophilia A program and in vivo gene editing technology. The 2seventy bio team will join Novo Nordisk, focusing on...
Via
Benzinga
Volkswagen Puts Our Rivian Bet In The Black: The Pros And Cons Of Trading Options Versus Stocks
June 27, 2024
Novo Nordisk, Carvana, And Now Rivian
Via
Benzinga
Novo Nordisk To Restrict Initial Wegovy Sales In China Amid High Demand
June 27, 2024
Novo Nordisk will limit initial sales of Wegovy in China to manage global supply and address the rising obesity rates in the world's most populous country. The competitive landscape and regulatory...
Via
Benzinga
Hims & Hers Health Stock Is Sliding Thursday: What's Going On?
June 27, 2024
Hunterbrook releases a bearish report alleging that Hims & Hers sells knockoff GLP-1 weight loss drugs and relies on a single supplier with previously unreported ties to fraud and bankruptcy.
Via
Benzinga
Topics
Fraud
Supply Chain
Exposures
Legal
Supply Chain
Ben & Jerry's Co-Founders Not Worried About Ozempic's Impact On Ice Cream Business: Here's Why
June 27, 2024
Ben Cohen and Jerry Greenfield, the co-founders of Ben & Jerry's, are not worried about the impact of weight-loss drugs on their ice cream business, despite the impending spin-off of their parent...
Via
Benzinga
Bernie Sanders: 'Ozempic Will Likely Become One Of The Best-Selling Pharmaceutical Products In History' — Americans Shouldn't Pay 10-15X More
June 26, 2024
Via
Benzinga
Novo Nordisk Halts Late-Stage Study Of Experimental Hypertension Drug, Takes Over $800M Impairment Charge
June 26, 2024
Novo Nordisk announced the failure of its phase 3 CLARION-CKD trial, which investigated ocedurenone for treating uncontrolled hypertension in advanced chronic kidney disease patients. The trial did not...
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
June 26, 2024
Via
Benzinga
The Next 7 Trillion-Dollar Stocks to Buy: June 2024 Edition
June 26, 2024
The next trillion dollar stocks have emerged in a few key areas that investors should understand in greater detail in order to profit.
Via
InvestorPlace
Better Growth Stock: Archer Aviation or Viking Therapeutics?
June 26, 2024
Which one of these potential disruptors is the better buy?
Via
The Motley Fool
Rivian, Lucid, Micron Technology, Novo Nordisk, Tesla: Why These 5 Stocks Are On Investors' Radars Today
June 25, 2024
On Tuesday, U.S. stocks showed mixed results. The Dow Jones Industrial Average closed down by nearly 0.8%, finishing at 39,112.16
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Novo Nordisk's Older Generation Weight-Loss Drug Saxenda Associated With Decreased Bone Mass Density, Study Shows
June 25, 2024
Novo Nordisk's Saxenda study published in JAMA Network Open reveals significant declines in bone density among patients, raising concerns for similar weight loss drugs.
Via
Benzinga
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
61
62
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.